Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASAP: Aggrenox vs. Aspirin for Stroke Prevention in Japan
NCT00311402Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2006
- Primary completion
- Mar 2009
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dipyridamole in cerebral infarction, sponsored by Boehringer Ingelheim. Primary endpoint: Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal) at 124 weeks. Started Apr 2006; status: completed.
02
Drugs
dipyridamole
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT00311402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311402.